Multiple Dose, Steady State-Partial reference replicate [Design Issues]
» Please help in understanding whether it is possible to conduct “An open-label, randomized, Multiple Dose, Steady State, two treatments, three periods, three sequence, three way, Reference Replicated crossover bioequivalence study” for USFDA Submission?
Yes to everything except (conditionally) the term 'three way' in the context of your post.
if (3) 4
"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.
- Multiple Dose, Steady State-Partial reference replicate - arl_stat, 2018-07-13 13:26 [Design Issues]
- Multiple Dose, Steady State-Partial reference replicate - ElMaestro, 2018-07-13 13:42
- Logistic nigthmare - Helmut, 2018-07-13 14:35
- Multiple Dose, Steady State-Partial reference replicate - jag009, 2018-07-17 06:34